Cancer Genetics Again Lowers Expected Proceeds from IPO to $23.5M | GenomeWeb

NEW YORK (GenomeWeb News) – Cancer Genetics has again lowered the amount it expects to bring in from its pending initial public offering, the Rutherford, NJ-based firm disclosed in a document filed with the US Securities and Exchange Commission late on Wednesday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: weighting scheme increases GWAS power, and more.

Marc Tessier-Lavigne is to be the next president of Stanford University.

Walgreens has given Theranos 30 days to fix its lab issues, the Wall Street Journal reports.

Journals and research funding agencies pledge to enable the sharing of Zika virus research.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.